» Articles » PMID: 8684798

Ophthalmic Manifestations of Smith-Magenis Syndrome

Overview
Journal Ophthalmology
Publisher Elsevier
Specialty Ophthalmology
Date 1996 Jul 1
PMID 8684798
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The Smith-Magenis syndrome (SMS) is a multiple-anomaly, mental retardation syndrome associated with deletions of a contiguous region of chromosome 17p11.2. Prior reports have described ophthalmic anomalies with SMS, including telecanthus, ptosis, strabismus, myopia, iris anomalies, cataracts, optic nerve hypoplasia, and retinal detachment. This report defines the ophthalmic spectrum in 28 individuals with SMS subjected to a multidisciplinary clinical and molecular survey.

Methods: Individuals with deletion of chromosome 17p11.2 detected by high-resolution cytogenetic analysis underwent complete ophthalmologic evaluation comprised of ophthalmic history, visual acuity, cycloplegic refraction, motility, and biomicroscopic and ophthalmoscopic examination.

Results: Among the 28 subjects, ranging in age from 0.8 to 29.3 years, the most frequent ocular findings were iris anomalies (68%), microcornea (50%), myopia (42%), and strabismus (32%). Bilateral microphthalmos with uveal and retinal coloboma was observed in one individual. No subject had cataract or retinal detachment.

Conclusions: This is the largest single-center series of subjects with SMS that includes ophthalmic evaluation. As in prior reports, iris anomalies and strabismus were observed, but microcornea had not been noted previously. The absolute refractive error was hypermetropic in half of these subjects. Cataract, ptosis, and retinal pathology, including detachment, were not observed in any subject. All individuals with SMS should be evaluated by an ophthalmologist, with special attention to strabismus, microcornea, iris anomalies, and refractive errors.

Citing Articles

Smith-Magenis Syndrome-Clinical Review, Biological Background and Related Disorders.

Rinaldi B, Villa R, Sironi A, Garavelli L, Finelli P, Bedeschi M Genes (Basel). 2022; 13(2).

PMID: 35205380 PMC: 8872351. DOI: 10.3390/genes13020335.


Neurodevelopmental Disorders Associated with Abnormal Gene Dosage: Smith-Magenis and Potocki-Lupski Syndromes.

Neira-Fresneda J, Potocki L J Pediatr Genet. 2016; 4(3):159-67.

PMID: 27617127 PMC: 4918721. DOI: 10.1055/s-0035-1564443.


Differences in Social Motivation in Children with Smith-Magenis Syndrome and Down Syndrome.

Wilde L, Mitchell A, Oliver C J Autism Dev Disord. 2016; 46(6):2148-2159.

PMID: 26983920 DOI: 10.1007/s10803-016-2743-3.


Smith-Magenis Syndrome: Face Speaks.

Gupta R, Gupta N, Nampoothiri S, Mandal K, Kishore Y, Sharma P Indian J Pediatr. 2015; 83(6):589-93.

PMID: 26676648 DOI: 10.1007/s12098-015-1940-y.


Behavioral disturbance and treatment strategies in Smith-Magenis syndrome.

Poisson A, Nicolas A, Cochat P, Sanlaville D, Rigard C, de Leersnyder H Orphanet J Rare Dis. 2015; 10:111.

PMID: 26336863 PMC: 4559928. DOI: 10.1186/s13023-015-0330-x.